2025 PACUPrep BCCCP Preparatory Course Endocarditis Transition of Care, De-Escalation, and Recovery Planning
Transition of Care, De-Escalation, and Recovery Planning in Infective Endocarditis

Transition of Care, De-Escalation, and Recovery Planning in Infective Endocarditis

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

Guide critical-care pharmacists through systematic de-escalation of intensive therapies, safe conversion to oral/OPAT regimens, mitigation of Post-ICU Syndrome, and comprehensive discharge and follow-up planning.

1. Criteria and Protocol for De-Escalation

De-escalation from broad-spectrum intravenous (IV) antibiotics to narrower, pathogen-directed therapy is a cornerstone of antimicrobial stewardship. This process hinges on sustained clinical stability, documented microbiologic clearance, and a formal multidisciplinary review.

A. Clinical Stability Benchmarks

  • Afebrile for at least 48 hours without antipyretics.
  • Two consecutive sets of blood cultures drawn ≥24 hours apart are negative.
  • Normalizing inflammatory markers (e.g., C-reactive protein, procalcitonin).
  • Hemodynamic stability with no vasopressor requirement for ≥24 hours.
  • No new or worsening embolic events, heart failure, or valvular dysfunction on follow-up echocardiography.

B. Timeline Guidance for Therapy Narrowing

  • Native-valve streptococcal IE: Consider narrowing therapy after 7–10 days of effective treatment.
  • Staphylococcal IE (MSSA/MRSA): Generally requires at least 14 days of initial bactericidal IV therapy before considering de-escalation.
  • Prosthetic-valve IE (PVE): Often requires an extended initial course of broad-spectrum and/or biofilm-active agents due to the complexity of eradication.

C. Multidisciplinary Review: The “Antimicrobial Time-Out”

A structured, daily review is critical for safe de-escalation. This should involve ICU physicians, infectious diseases specialists, clinical pharmacists, and bedside nursing to:

  • Review pathogen identification and final susceptibility results.
  • Formally assess the patient against clinical stability benchmarks.
  • Make a consensus decision to continue, narrow, or stop specific agents.
  • Clearly document the rationale for all antimicrobial decisions in the medical record.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Clinical Pearls
  • Use a daily antimicrobial “time-out” checklist to formalize the de-escalation discussion and curb unnecessary broad-spectrum use.
  • Delay de-escalation in MRSA or prosthetic-valve cases until robust biofilm-active therapy (e.g., rifampin, if susceptible) has been administered for an adequate duration.
  • Reassess echocardiographic findings before each major de-escalation step to rule out new or silent complications.

2. Intravenous to Enteral Conversion

A safe switch from IV to oral (PO) or enteral therapy requires careful patient selection, use of agents with high bioavailability, and diligent monitoring for absorption and toxicity.

A. Candidate Selection Criteria

  • Sustained hemodynamic stability and afebrile status.
  • A fully functional and accessible gastrointestinal tract.
  • Definitive source control has been achieved (if applicable).
  • Negative repeat blood cultures are documented.
  • The causative pathogen is confirmed to be susceptible to the proposed oral agents.

B. High-Bioavailability Oral Agents for IE

Common High-Bioavailability Oral Agents for IE Step-Down Therapy
Agent Bioavailability Standard Oral Dose Key Monitoring
Levofloxacin ~99% 750 mg once daily Renal function (CrCl); QT interval with baseline ECG
Linezolid ~100% 600 mg every 12 hours Weekly CBC (thrombocytopenia); serotonin syndrome risk
Moxifloxacin ~90% 400 mg once daily Hepatic function; QT interval with baseline ECG
Ciprofloxacin ~70% 750 mg every 12 hours Renal function; risk of tendon toxicity

C. Enteral Tube and PK/PD Considerations

  • Administration: Ensure tablets are crushable and flush tubes adequately before and after dosing to prevent clogging and ensure full delivery.
  • Absorption: For patients with impaired GI motility or on continuous tube feeds, consider validating absorption with a test dose and subsequent drug level monitoring if available.
  • Dose Adjustments: Proactively monitor for and manage potential toxicities. This includes weekly CBCs for linezolid (avoiding use >28 days), baseline and follow-up ECGs for fluoroquinolones in at-risk patients, and renal dose adjustments for levofloxacin/ciprofloxacin.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Clinical Pearls
  • Always confirm GI absorption is adequate in patients receiving enteral feeds, especially if their clinical response is suboptimal.
  • For difficult-to-treat pathogens, consider combining two oral agents with complementary mechanisms (e.g., linezolid plus rifampin) for synergistic activity.
  • Avoid oral rifampin monotherapy due to the high risk of rapid resistance development. It must be used as part of a combination regimen.

3. Post-ICU Syndrome (PICS) Prevention

PICS is a constellation of new or worsened physical, cognitive, and psychological impairments that persist after critical illness. Proactive mitigation using the ABCDEF bundle is essential.

A. Risk Factors and the ABCDEF Bundle

Key risk factors include advanced age, preexisting frailty, and prolonged mechanical ventilation or deep sedation. The ABCDEF bundle provides a systematic framework to combat these risks.

ABCDEF Bundle for ICU Care A flowchart illustrating the six components of the ABCDEF bundle: A for Assess Pain, B for Both SAT/SBT, C for Choice of Sedation, D for Delirium, E for Early Mobility, and F for Family Engagement. A Assess, Prevent & Manage Pain B Both SAT & SBT (Awakening/Breathing) C Choice of Sedation (Light sedation) D Delirium: Assess, Prevent & Manage E Early Mobility & Exercise F Family Engagement & Empowerment
Figure 1: The ABCDEF Bundle. A multidisciplinary, evidence-based approach to improve ICU patient outcomes and reduce the incidence of Post-ICU Syndrome (PICS).

B. Nutritional and Psychological Support

  • Nutrition: Involve a registered dietitian early to initiate enteral feeding, optimize caloric and protein intake, and prevent malnutrition-related complications.
  • Mental Health: Routinely screen for anxiety, depression, and post-traumatic stress using validated tools. Engage psychology or psychiatry services as needed for patient and family support.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Clinical Pearls
  • Initiate passive range-of-motion exercises within 48 hours of ICU admission, even in sedated patients, to prevent ICU-acquired weakness.
  • Screen for delirium at least twice daily using a validated tool like the CAM-ICU. Implement non-pharmacologic sleep protocols (e.g., minimizing nighttime disruptions) as a first-line prevention strategy.
  • Actively engage family members in daily care by encouraging them to help with patient reorientation, provide emotional support, and participate in goal-setting discussions.

4. Medication Reconciliation and Discharge Counseling

A structured medication reconciliation process combined with patient-centered education at each transition of care is paramount to reducing medication errors and improving long-term adherence.

A. Three-Step Reconciliation Workflow

Pharmacists should lead a meticulous reconciliation process at three key points to ensure medication safety and continuity.

Medication Reconciliation Workflow A three-step flowchart showing the medication reconciliation process: Step 1 at Admission, Step 2 at Discharge, and Step 3 at the First Outpatient Visit. 1. Admission Verify pre-hospital meds and allergies. 2. Discharge Reconcile inpatient vs. planned outpatient list. 3. First Follow-Up Confirm accuracy and adherence.
Figure 2: The Pharmacist-Led Medication Reconciliation Cycle. A continuous loop of verification ensures medication safety across care transitions.

B. Discharge Counseling Checklist

  • Purpose & Duration: Clearly state the indication and total duration for each antibiotic and key adjunctive medication.
  • Administration Details: Provide specific instructions on administration (e.g., with or without food, timing relative to other drugs, specifics for enteral tube).
  • Monitoring Plan: Explain the schedule for required lab tests, echocardiograms, and any other specialized monitoring (e.g., audiology for aminoglycoside recipients).
  • Signs of Relapse: Educate the patient and family on critical signs and symptoms of relapse to watch for, such as fever, chills, night sweats, malaise, or a new heart murmur.

C. Effective Education Strategies

  • Teach-Back Method: Ask the patient or caregiver to explain the plan in their own words to confirm understanding.
  • Written Materials: Provide clear, written instructions, preferably in a low-literacy format with large font and simple language.
  • Post-Discharge Follow-up: A pharmacist-led phone call within 48-72 hours of discharge can identify and resolve early problems with medication access or adherence.

5. Outpatient Parenteral (OPAT) and Oral Therapy (POET) Plans

Completing a long course of antibiotics outside the hospital via OPAT or a partial oral regimen (as supported by the POET trial) can significantly reduce length of stay, healthcare costs, and hospital-acquired complications.

A. OPAT Infrastructure and Patient Selection

A successful OPAT program requires robust infrastructure and careful patient selection.

  • Essentials: Coordinated home health or infusion center nursing for line care, reliable access to ambulatory infusion pumps, clear emergency contacts, and a system for outpatient lab draws.
  • Patient Selection: Candidates must be clinically stable with no active complications, have a safe and supportive home environment, and demonstrate the ability to manage their own care or have a reliable caregiver.

B. Highlights from the POET Trial

The Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis (POET) trial was a landmark study supporting this practice in stable, left-sided IE patients.

  • Patients were stabilized on IV therapy for at least 10 days before being randomized.
  • The primary composite outcome (all-cause mortality, unplanned cardiac surgery, embolic events, or relapse) was non-inferior in the oral step-down group (9.0%) compared to the continued IV group (12.1%).
  • The median post-randomization hospital stay was dramatically shorter in the oral group (3 days) versus the IV group (19 days).

C. Monitoring and Device Selection

  • Monitoring Schedule: Typically includes weekly labs (renal panel, hepatic panel, CBC) and a follow-up echocardiogram 4–6 weeks after therapy completion.
  • Device Choice: For OPAT courses expected to last less than 14 days, a midline catheter may be preferred over a PICC line to reduce the risk of deep vein thrombosis (DVT).
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Clinical Pearls
  • Coordinate OPAT plans in writing among pharmacy, nursing, and laboratory services before discharge to ensure a seamless transition.
  • Establish clear escalation protocols for patients to follow in case of line issues (e.g., occlusion, redness) or infusion complications.
  • Use a shared decision-making model to select an oral vs. IV continuation plan, factoring in pathogen susceptibility, patient preference, and available social support.

6. Long-Term Follow-Up and Prevention

Recovery from IE is a long-term process. Continued surveillance, secondary prevention strategies, and multidisciplinary care are essential to reduce the risk of relapse and address late sequelae.

A. Dental Health and Prophylaxis

  • Evaluation: All IE survivors should undergo a comprehensive dental evaluation within one month of completing therapy to identify and treat any potential sources of bacteremia.
  • Hygiene: Emphasize the lifelong importance of meticulous oral hygiene, including regular brushing, flossing, and professional dental cleanings.
  • Prophylaxis: Antibiotic prophylaxis is indicated for high-risk patients (e.g., those with prosthetic valves, previous IE, or certain congenital heart conditions) undergoing invasive dental procedures that involve manipulation of gingival tissue.

B. Care Coordination and the Survivorship Model

A coordinated, multidisciplinary approach is key to long-term success.

  • Primary Care: Manages chronic comorbidities and reinforces medication adherence.
  • Cardiology: Monitors long-term valve function with serial echocardiography and refers for surgical evaluation if hemodynamically significant valve dysfunction develops.
  • Rehabilitation: Addresses physical deconditioning with physical/occupational therapy and manages cognitive deficits with appropriate therapies.
  • Survivorship Clinic: An ideal model combines ID, cardiology, and pharmacy services into integrated visits to provide holistic management of medical, psychosocial, and rehabilitation needs.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Clinical Pearls
  • Champion the development of an “endocarditis survivorship” clinic to provide integrated, long-term care and improve outcomes.
  • Tailor the frequency of follow-up echocardiography based on the patient’s clinical status, the type of valve involved (native vs. prosthetic), and the presence of any residual dysfunction.
  • Reinforce the importance of both dental hygiene and general cardiovascular risk factor modification at every follow-up visit.

References

  1. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435–1486.
  2. Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019;380(5):415–424.
  3. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004;38(12):1651–1672.
  4. McDonald EG, Yilmaz D, Hachim M, et al. Association of a Pharmacist-Led Postdischarge Antimicrobial Stewardship Intervention With Reduced Readmissions and Emergency Department Visits. JAMA Netw Open. 2023;6(7):e2326366.
  5. Mazzitelli D, Botta L, Trunfio M, et al. The role of the Endocarditis Team in the management of infective endocarditis: a narrative review. Ann Cardiothorac Surg. 2024;13(3):345–355.
  6. Iversen K, Gill SU, Hvitfeldt Poulsen S, et al. Partial oral treatment of endocarditis. Am Heart J. 2013;165(1):116–122.
  7. Rajaratnam D, Bond A, Graf V, et al. A Narrative Review of Oral Antibiotic Therapy in Infective Endocarditis. Infect Dis Ther. 2023;12(1):1–14.
  8. Verhagen DW, Vedder AC, Speelman P, et al. Antimicrobial treatment of prosthetic valve endocarditis. Clin Infect Dis. 2009;48(11):1559–1565.
  9. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation. 2007;116(15):1736–1754.
  10. Folwaczny M, Louloudiadis K, Walter C, et al. Dental aspects of infective endocarditis. Cardiovasc Diagn Ther. 2021;11(6):1403–1415.
Previous Topic
Back to Lesson
Next Lesson